C2N Diagnostics Launches FDA-Cleared PrecivityAD2® Test to Improve Alzheimer’s Disease Diagnosis in Symptomatic Patients

C2N Diagnostics Launches FDA-Cleared PrecivityAD2 Blood Test to Improve Alzheimer’s Disease Diagnosis

C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing innovative solutions for neurological conditions, has announced the availability of the FDA-cleared version of its PrecivityAD2® blood test for healthcare professionals across the United States. The test is designed to support the evaluation of adults experiencing cognitive symptoms by providing important information about the likelihood of brain amyloid pathology, a defining biological characteristic of Alzheimer’s disease.

The availability of the FDA-cleared PrecivityAD2 test represents an important development in the advancement of blood-based diagnostic tools for Alzheimer’s disease. By offering a less invasive approach to assessing key disease-related biomarkers, the test aims to help healthcare professionals obtain valuable diagnostic information and make more informed decisions regarding patient care.

Alzheimer’s disease is a progressive neurological condition that affects memory, thinking, behavior and the ability to perform everyday activities. Early identification of the disease is particularly important because treatment decisions and access to disease-modifying therapies may depend on the stage at which the condition is diagnosed. However, identifying Alzheimer’s disease can be challenging because cognitive symptoms may arise from several underlying causes, requiring healthcare professionals to undertake a comprehensive diagnostic evaluation.

The PrecivityAD2 blood test is intended to help simplify this process by measuring specific biomarkers associated with Alzheimer’s-related brain pathology. Healthcare professionals can use the results alongside clinical assessments and other relevant patient information to evaluate individuals experiencing memory problems or other signs of cognitive decline.

The test combines measurements of phosphorylated tau 217 (%p-tau217) and the amyloid-beta 42/40 ratio (Aβ42/40), two biomarkers associated with Alzheimer’s disease pathology. Using high-resolution mass spectrometry and a proprietary algorithm, the test calculates an Amyloid Probability Score 2 (APS2). This score indicates the likelihood that a patient has brain amyloid pathology, providing clinicians with additional information to support diagnostic decision-making.

Through its nationwide availability, C2N aims to expand access to advanced blood-based Alzheimer’s diagnostics and help address challenges associated with the identification and evaluation of patients with cognitive impairment.

PrecivityAD2 Uses Advanced Biomarker Analysis to Assess Alzheimer’s Pathology

The PrecivityAD2 test incorporates advanced analytical technology to measure two important biological indicators associated with Alzheimer’s disease. These include phosphorylated tau 217 and the amyloid-beta 42/40 ratio.

Phosphorylated tau 217 is a biomarker associated with changes in tau protein that occur in the brain during Alzheimer’s disease. Abnormal tau-related changes are closely linked to the biological processes involved in the progression of the condition. Measuring %p-tau217 can therefore provide valuable information about disease-related biological activity.

The amyloid-beta 42/40 ratio provides additional information about amyloid-related pathology. Amyloid-beta proteins can accumulate in the brain and form plaques, which are considered one of the characteristic pathological features of Alzheimer’s disease. Evaluating the relative levels of amyloid-beta 42 and 40 helps assess the likelihood of amyloid pathology.

To generate the final result, PrecivityAD2 combines these two biomarker measurements through C2N’s proprietary algorithm. The resulting Amyloid Probability Score 2 integrates the biomarker information into a score that helps healthcare professionals assess whether brain amyloid pathology is likely to be present.

The test uses high-resolution mass spectrometry, an analytical technology that enables precise measurement of specific molecules and biomarkers in biological samples. This approach supports the accurate assessment of the biomarkers used in the APS2 calculation.

The resulting information can help clinicians determine appropriate next steps in the diagnostic process. Depending on the patient’s symptoms, medical history and overall clinical assessment, these decisions may include additional diagnostic investigations or consideration of disease-modifying treatment options.

Importantly, the PrecivityAD2 test is intended to support clinical evaluation rather than independently establish an Alzheimer’s disease diagnosis. Healthcare professionals must interpret the results in the context of the patient’s symptoms, medical history and other relevant clinical findings.

FDA-Cleared Test Expands Access to Blood-Based Alzheimer’s Diagnostics

One of the notable characteristics of the FDA-cleared PrecivityAD2 test is its intended use in adults experiencing cognitive symptoms, including individuals as young as 40 years old.

According to C2N, PrecivityAD2 is the first FDA-cleared Alzheimer’s test for adults with cognitive symptoms in this age group. This expands the availability of blood-based diagnostic support to a broader population of patients who may be experiencing memory-related concerns.

The test was validated across different clinical characteristics, including patient age, sex and disease stage. This validation is important because Alzheimer’s disease can affect individuals differently, and diagnostic tools must demonstrate reliable performance across diverse patient populations.

C2N also highlighted the test’s consistent performance across several commonly encountered comorbidities. These include metabolic, cardiovascular, autoimmune, oncology-related, mental health and renal disorders.

The presence of additional medical conditions can complicate the assessment of cognitive impairment. Patients may experience memory or cognitive difficulties alongside other chronic health conditions, making it important for diagnostic tools to demonstrate reliable performance across different clinical circumstances.

By evaluating the test across these characteristics and comorbidities, C2N aims to provide healthcare professionals with a diagnostic tool that can support the assessment of a wide range of patients.

The company also indicated that the test can help healthcare professionals assess the likelihood of brain amyloid pathology in both primary care and specialized healthcare settings. Its use is intended for healthcare professionals experienced in evaluating cognitive impairment.

This broader clinical applicability could help improve the diagnostic pathway for patients who initially present with memory concerns in primary care before potentially being referred to specialists for further assessment.

Supporting Earlier Identification and Treatment Decisions

Timely identification of Alzheimer’s disease has become increasingly important as disease-modifying treatment options continue to advance. Several therapeutic approaches are designed to address the underlying biological processes associated with the disease rather than simply managing symptoms.

However, access to these treatments may depend on confirming the presence of relevant Alzheimer’s pathology and identifying patients who are at an appropriate stage of disease progression.

For individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease, determining whether brain amyloid pathology is present can be an important part of evaluating eligibility for certain approved disease-modifying therapies.

Traditional diagnostic pathways can involve multiple assessments and procedures, which may create delays for patients and their families. Blood-based biomarkers offer an opportunity to make the diagnostic process more accessible by providing clinically relevant information through a blood test.

The availability of FDA-cleared PrecivityAD2 could therefore help healthcare professionals gather important diagnostic evidence earlier in the evaluation process. By combining two Alzheimer’s-related biomarkers into a single probability score, the test may help clinicians determine which patients require additional investigations and support decisions about subsequent care.

The broader adoption of validated blood-based biomarkers could also contribute to more efficient healthcare delivery by helping clinicians better identify patients who may benefit from additional diagnostic testing or specialist evaluation.

Milken Institute Highlights the Importance of Early Detection

Michael Brown, director of the Alliance to Improve Dementia Care, a program of the Milken Institute’s Future of Aging and Longevity, emphasized the importance of timely and accurate identification of Alzheimer’s disease pathology.

Brown noted that an estimated 2,000 to 3,000 Medicare beneficiaries with Alzheimer’s disease pathology progress beyond the window of approved disease-modifying therapies every day. These therapies are indicated for patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease.

His comments highlight the significant consequences that diagnostic delays can have for patients who may otherwise qualify for available treatment options.

The timing of diagnosis is particularly important because the effectiveness and suitability of disease-modifying therapies can depend on the stage of the disease. Patients who are identified after progressing beyond the stages covered by treatment indications may have fewer opportunities to benefit from these therapeutic options.

The Milken Institute has also addressed the growing role of blood-based biomarkers in improving Alzheimer’s disease diagnosis and cognitive care.

In its latest report on advancing blood-based biomarkers for Alzheimer’s disease, the institute called on healthcare systems to accelerate the adoption of well-validated blood biomarker technologies as a standard component of care for patients experiencing signs and symptoms of cognitive decline.

The report emphasizes the need for healthcare systems to improve diagnostic efficiency and ensure that patients can access appropriate testing and evaluation without unnecessary delays.

The increasing availability of validated blood-based diagnostic technologies could play an important role in addressing these challenges. Tests such as PrecivityAD2 may help provide additional biological information during the clinical evaluation process, supporting more informed decisions and potentially improving access to appropriate care.

Patient Experience Highlights the Value of Earlier Testing

The potential impact of blood-based Alzheimer’s diagnostic testing is also reflected in the experience of patients and their families.

Chris Cronin, a 60-year-old resident of Ballwin, Missouri, previously underwent testing with an earlier version of the Precivity blood test after his wife and sister noticed changes in his memory.

The concerns raised by his family prompted him to seek medical evaluation and undergo testing to better understand the possible cause of his cognitive difficulties.

Although the results were not what he and his family had hoped for, the test provided important information that helped him begin treatment for early-onset Alzheimer’s disease sooner than might otherwise have been possible.

Cronin explained that receiving the results gave him an opportunity to move forward with treatment and better understand his condition.

He also expressed optimism about the broader availability of the FDA-cleared PrecivityAD2 test, highlighting the potential benefits for other individuals experiencing memory-related symptoms.

According to Cronin, making the test available to more patients could help people obtain important information about their cognitive health and receive answers that may guide their next steps.

His experience illustrates the importance of recognizing early cognitive changes and pursuing appropriate medical evaluation. Family members frequently play an important role in identifying changes in memory, behavior or everyday functioning that may warrant further investigation.

The availability of blood-based diagnostic tools could help patients and families navigate the evaluation process with greater access to information about potential underlying disease pathology.

C2N Diagnostics Advances Its Alzheimer’s Diagnostic Portfolio

The launch of the FDA-cleared PrecivityAD2 test builds on C2N Diagnostics’ ongoing work in developing innovative diagnostic technologies for neurological conditions.

The company focuses on specialty diagnostics and aims to improve clinical decision-making through advanced biomarker analysis and precision measurement technologies.

Its Precivity platform has been developed to address the need for improved tools in the evaluation of Alzheimer’s disease. The availability of the FDA-cleared version of PrecivityAD2 represents another milestone in the company’s efforts to expand access to blood-based testing for patients experiencing cognitive symptoms.

Dr. Joel Braunstein, co-founder, chief executive officer and president of C2N Diagnostics, described the availability of the test as an important milestone for the company.

Braunstein stated that C2N had been anticipating this development since the FDA initially informed the company that its review had cleared the PrecivityAD2 test.

He emphasized that making the test available nationwide through healthcare professionals would provide patients and families with a clearer understanding of brain amyloid plaque, a characteristic feature of Alzheimer’s disease.

According to Braunstein, the test could also help streamline and simplify the complex diagnostic pathway that many patients encounter when seeking answers about serious memory concerns.

The company’s objective is to provide healthcare professionals with additional diagnostic information that can support the evaluation of cognitive impairment and help guide appropriate clinical decisions.

Growing Role of Blood Biomarkers in Alzheimer’s Disease Management

The introduction of FDA-cleared blood-based diagnostic technologies reflects a broader shift toward biomarker-driven approaches in Alzheimer’s disease management.

Historically, confirming amyloid pathology has often involved more complex diagnostic procedures, including specialized brain imaging and cerebrospinal fluid testing. Although these methods remain important clinical tools, access, cost, availability and patient considerations can create challenges.

Blood-based biomarkers offer an additional approach that may help make the assessment of Alzheimer’s-related pathology more accessible.

As research continues to advance, biomarkers such as phosphorylated tau and amyloid-beta are becoming increasingly important in identifying the biological characteristics of Alzheimer’s disease.

The development of validated blood tests could support more efficient patient evaluation, particularly when integrated into established clinical pathways.

Nevertheless, the successful implementation of these technologies will depend on appropriate clinical interpretation, healthcare professional education and broader adoption across healthcare systems.

C2N’s FDA-cleared PrecivityAD2 test is positioned to contribute to this evolving diagnostic landscape by providing healthcare professionals with a blood-based method for assessing the likelihood of brain amyloid pathology.

Nationwide Availability Marks an Important Milestone

With the FDA-cleared version of PrecivityAD2 now available for ordering by healthcare professionals, C2N Diagnostics is expanding access to its biomarker-based approach to Alzheimer’s disease evaluation.

The test measures %p-tau217 and Aβ42/40 using high-resolution mass spectrometry and combines the results through a proprietary algorithm to generate the Amyloid Probability Score 2.

Its validation across different patient characteristics and common comorbidities, together with its intended use in adults aged 40 and older who experience cognitive symptoms, highlights its potential role in supporting clinical assessment.

As healthcare systems increasingly focus on earlier identification of Alzheimer’s disease, validated blood-based biomarkers may become an important component of diagnostic pathways.

The availability of PrecivityAD2 is expected to provide healthcare professionals with another tool to evaluate patients experiencing cognitive decline, assess the likelihood of amyloid pathology and determine appropriate next steps in care.

About C2N Diagnostics

C2N is a leading specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health.

C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world.

This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter